查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1835398

关节痛注射剂市场（按分子类型、适应症、给药途径、最终用户和患者年龄组划分）—全球预测，2025-2032

Joint Pain Injections Market by Molecule Type, Indication, Route Of Administration, End User, Patient Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年关节痛注射剂市场规模将达到 118.5 亿美元，复合年增长率为 11.25%。

主要市场统计数据
基准年2024年 50.4亿美元
预计2025年 56.2亿美元
预测年份：2032年 118.5亿美元
复合年增长率（%） 11.25%

为决策者全面介绍影响全球关节痛注射生态系统的临床、技术和商业性驱动因素

随着临床医生寻求有效、有针对性的干预措施，以最大程度地减轻症状并缩短恢復期，关节疼痛注射已成为现代整形外科、风湿病学和运动医学的核心。在过去十年中，临床医生在现有的皮质类固醇注射疗法与不断扩展的生物製药和关节内粘稠补充疗法之间取得了平衡，技术和影像引导对治疗结果的重要性日益凸显。因此，临床讨论已从单一治疗模式转向以安全性、可重复性和患者报告的功能改善为优先考虑的综合治疗途径。

如今，临床医生和医疗保健系统面临着巨大的报销压力、患者对无针再生疗法的需求日益增长，以及对手术部位安全性和文件记录日益重视等诸多挑战。此外，微创手术在门诊（例如门诊手术中心和专科诊所）的应用正在加速，这影响着筹资策略和培训重点。这些因素共同作用，挑战製造商、设备製造商和临床服务供应商，他们需要协调产品创新、医生教育和价值展示，以保持应用率并满足付款人的期望。

探索加速注射疗法治疗关节疼痛和改变护理标准的变革性技术、临床和政策转变

由于生物製药、影像学和报销模式的融合，关节疼痛注射疗法的临床和商业性前景正在发生重大变化。首先，临床上对再生疗法的兴趣日益浓厚，已将富血小板血浆和相关的自体血浆疗法从小众选择提升到主流临床实验选择，促使製造商改进处理试剂套件和品管。同时，改良的透明质酸配方和皮质类固醇的持续使用保持了其治疗相关性，但根据患者情况和关节特异性结果，其治疗方案会更加细緻。

同时，影像引导介入措施（例如超音波引导注射）正从专科中心走向常规实践，从而提高了靶向精准度，并强化了其对卓越临床疗效和降低併发症率的主张。医疗系统和支付方正在做出回应，强调程序记录和真实世界结果，并增加对资料收集和品质登记的投入。最后，随着供应链弹性、本地製造和策略伙伴关係对于管理成本压力和监管复杂性变得至关重要，该领域的商业逻辑正在转变。随着相关人员的适应，将临床证据产生与临床医生培训和强大的上市后监测相结合的公司将在采用和信任方面实现非对称优势。

严格分析 2025 年美国关税如何改变注射关节痛疗法的采购、定价和供应链策略。

美国2025年实施的关税变化的累积效应波及了关节疼痛注射剂及其组件的采购、定价和供应链决策。某些进口医疗用品的关税上调，增加了一次性套件、透明质酸起始原料和某些器械组件的到岸成本，促使企业即时与供应商进行谈判，并重新评估筹资策略。为此，跨国製造商加快了本地化生产的步伐，将高价值组装转移到国内，或在关税豁免地区重新寻找替代供应商，以减轻利润率的压缩。

这种转变导致采购週期延长，供应商、经销商和医疗保健提供者组织之间需要重新谈判合约并进行成本转嫁讨论。付款人和医院采购团队越来越严格地审查单位经济效益和总护理成本，这更凸显了製造商证明持续临床效益和成本抵销的必要性。同时，规模较小的创新者和契约製造製造商面临越来越大的进入美国市场的障碍，除非他们调整定价模式或建立国内合作伙伴关係。展望未来，法规合规性、关税分类明确以及双边供应商协议已成为相关人员在管理商业性可行性的同时寻求保持准入的关键战术性槓桿。

详细的细分洞察将分子类型、临床指征、给药途径、医疗环境和患者人口统计与可行的采用策略联繫起来

以分子类型评估时，可区分现有的皮质类固醇、各种透明质酸製剂和富血小板血浆方法，每种方法都有不同的临床和商业性意义。皮质类固醇类别包括已充分錶征的药物，例如Betamethasone、Methylprednisolone和曲安奈德，其效力、储库行为和症状缓解持续时间的差异影响着临床医生的选择。透明质酸製剂分为交联製剂和直链製剂；交联製剂通常旨在延长关节内停留时间和延长症状控制时间，而直链製剂则强调方便、低黏度和即时的关节顺应性。富血小板血浆分为白血球贫乏和白血球丰富的製剂；这些生物学差异影响发炎特征、监管监督和程序处理要求。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 快速采用生物製药的关节内粘稠补充疗法疗法治疗晚期骨关节炎疼痛
  • 将富血小板血浆注射与个人化再生通讯协定结合，用于关节修復
  • 扩大长效皮质类固醇製剂可减少注射频率并提高顺从性
  • 增加对微创超音波导引註射技术的投资，实现精准给药
  • 推出结合玻尿酸和干细胞成分的联合治疗，以提高疗效

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章关节痛注射剂市场（依分子类型）

  • 皮质类固醇
    • Betamethasone
    • 醋酸Methylprednisolone
    • 曲安奈德
  • 玻尿酸
    • 交联
    • 直链
  • 富血小板血浆
    • 少白血球
    • 多发性白血球

第九章关节痛注射剂市场（依适应症）

  • 痛风
    • 急性期管理
    • 慢性期管理
  • 骨关节炎
    • 髋关节
    • 膝关节
    • 肩关节
  • 类风湿性关节炎
    • 大关节
    • 小关节

第 10 章关节痛注射剂市场（依给药途径）

  • 关节内
    • 地标基地
    • 超音波引导
  • 肌肉注射
    • 深层组织
    • 浅部
  • 关节周围
    • 地标基地
    • 超音波引导

第 11 章 关节痛注射剂市场（依最终使用者）

  • 门诊手术中心
  • 医院
  • 整形外科诊所
  • 风湿病诊所

第十二章关节痛注射市场（依患者年龄层）

  • 青年
  • 成人
  • 老年人
  • 孩子们

第十三章关节痛注射市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章关节痛注射剂市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章关节痛注射剂市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Sanofi SA
    • Ferring Pharmaceuticals A/S
    • Zimmer Biomet Holdings, Inc.
    • Bioventus, Inc.
    • Seikagaku Corporation
    • Anika Therapeutics, Inc.
    • Fidia Farmaceutici SpA
    • Merck & Co., Inc.
    • Johnson & Johnson
    • AbbVie Inc.
Product Code: MRR-43470FC6083D

The Joint Pain Injections Market is projected to grow by USD 11.85 billion at a CAGR of 11.25% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.04 billion
Estimated Year [2025] USD 5.62 billion
Forecast Year [2032] USD 11.85 billion
CAGR (%) 11.25%

Comprehensive introduction to the clinical, technological, and commercial drivers reshaping the global joint pain injection ecosystem for decision-makers

Joint pain injections occupy a central role in contemporary orthopedics, rheumatology, and sports medicine as clinicians seek effective, targeted interventions that offer symptom relief with minimal downtime. Over the past decade, clinicians have balanced established corticosteroid injections with an expanding repertoire of biologic and viscosupplementation options, while procedural technique and imaging guidance have become increasingly pivotal to outcomes. As a result, the clinical conversation has shifted from single-treatment paradigms toward integrated pathways that prioritize safety, reproducibility, and patient-reported functional gains.

Clinicians and health systems now operate within a context defined by tighter reimbursement pressures, growing patient demand for needle-sparing and regenerative approaches, and heightened attention to procedure-site safety and documentation. In addition, outpatient settings such as ambulatory surgical centers and specialty clinics are accelerating adoption of minimally invasive interventions, which in turn shapes procurement strategies and training priorities. Taken together, these forces are prompting manufacturers, device makers, and clinical service providers to align product innovation, physician education, and value demonstration to sustain adoption and to address payer expectations.

Detailed exploration of transformative technological, clinical, and policy shifts that are accelerating adoption and changing standards of care in joint pain injection therapies

Clinical practice and commercial landscapes for joint pain injections are undergoing transformative shifts driven by converging advances in biologics, imaging, and reimbursement frameworks. First, the increasing clinical interest in regenerative approaches has elevated platelet-rich plasma and related autologous therapies from niche options to mainstream investigational choices, prompting manufacturers to refine processing kits and quality controls. Meanwhile, improvements in hyaluronic acid formulations and the continued use of corticosteroids maintain their therapeutic relevance, but with more nuanced positioning based on patient profile and joint-specific outcomes.

Concurrently, imaging-enabled delivery, most notably ultrasound-guided injections, has moved from specialized centers into routine practice, improving targeting accuracy and reinforcing claims of superior clinical outcomes and reduced complication rates. Health systems and payers are responding by emphasizing procedure documentation and real-world outcomes, which drives greater investment in data capture and quality registries. Finally, the sector's commercial logic is shifting as supply chain resilience, localized manufacturing, and strategic partnerships become critical to managing cost pressures and regulatory complexity. As stakeholders adapt, those who integrate clinical evidence generation with clinician training and robust post-market surveillance will realize asymmetric advantages in adoption and trust.

Rigorous analysis of how U.S. tariff measures enacted in 2025 reshaped sourcing, pricing dynamics, and supply chain strategies for joint pain injection therapies

The cumulative effects of tariff changes implemented in the United States in 2025 have reverberated across procurement, pricing, and supply chain decision-making for joint pain injection products and their components. Increased duties on certain imported medical inputs elevated landed costs for disposable kits, hyaluronic acid starting materials, and certain device components, which in turn prompted immediate supplier negotiations and a reevaluation of sourcing strategies. In response, multinational manufacturers accelerated efforts to localize production, shift higher-value assembly onshore, or requalify alternative suppliers in tariff-exempt jurisdictions to mitigate margin compression.

As a consequence of these shifts, procurement cycles lengthened while contract renegotiations and cost-pass-through discussions took place between suppliers, distributors, and provider organizations. Payers and hospital procurement teams increasingly scrutinized unit economics and total cost of care, reinforcing the need for manufacturers to demonstrate durable clinical benefit and cost-offsets. At the same time, smaller innovators and contract manufacturers faced heightened barriers to entering the U.S. market unless they adapted pricing models or established domestic partnerships. Looking forward, regulatory compliance, customs classification clarity, and bilateral supplier agreements have become critical tactical levers for stakeholders seeking to preserve access while managing commercial viability.

In-depth segmentation insights that connect molecule types, clinical indications, routes of administration, care settings, and patient age cohorts to practical adoption strategies

When evaluated by molecule type, the landscape distinguishes between established corticosteroids, various hyaluronic acid formulations, and platelet-rich plasma approaches, each presenting distinct clinical and commercial implications. The corticosteroid segment includes well-characterized agents such as Betamethasone, Methylprednisolone Acetate, and Triamcinolone Acetonide, with differences in potency, depot behavior, and duration of symptom relief influencing clinician selection. Hyaluronic acid offerings diverge across cross-linked and linear formulations, where cross-linked variants often aim to extend residence time within the joint and target longer symptom control, while linear formulations emphasize simplicity, lower viscosity, and potentially better immediate joint compliance. Platelet-rich plasma is differentiated into leukocyte-poor and leukocyte-rich preparations, and these biologic distinctions affect inflammatory profiles, regulatory oversight, and procedural handling requirements.

Based on indication, treatment pathways vary across gout, osteoarthritis, and rheumatoid arthritis. In gout the focus separates acute management from chronic management, which drives differences in medication choice and urgency of intervention. Osteoarthritis practice differentiates by joint site-hip, knee, and shoulder-with knee injections historically representing the largest procedural volume while hip and shoulder approaches demand higher imaging precision. Rheumatoid arthritis requires a different framing, as care pathways for large joints and small joints prioritize systemic disease control alongside local symptom relief.

Based on route of administration, clinicians select between intra-articular, intramuscular, and peri-articular approaches, with intra-articular procedures further distinguished by landmark-based or ultrasound-guided techniques. Intramuscular injections split into deep tissue and superficial approaches, each with distinct needle selection and recovery considerations, while peri-articular delivery also differentiates by landmark-based versus ultrasound-guided methods that affect accuracy and complication risk. Based on end user, the services are delivered across ambulatory surgical centers, hospitals, orthopedic clinics, and rheumatology clinics, with each setting imposing different credentials, billing pathways, and throughput constraints. Based on patient age group, clinical decision-making must account for adolescents, adults, elderly patients, and pediatrics, where comorbidities, growth considerations, and long-term safety profiles shape both product selection and procedural planning.

Collectively, these multi-dimensional segmentation lenses reveal that clinical adoption and commercial success hinge on aligning formulation properties, delivery technique, and site-of-care logistics with payer expectations and patient-centric outcomes. As a result, product teams and clinician educators must tailor evidence generation and training to specific molecule-route-indication permutations to accelerate acceptance and optimize outcomes.

Key regional perspectives highlighting how reimbursement, regulation, clinical practice patterns, and manufacturing capacity vary across major global regions

Regional dynamics continue to drive differentiated strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific, with each region presenting unique regulatory environments, reimbursement frameworks, and clinical practice patterns. In the Americas, a concentrated emphasis on outpatient procedural growth, ambulatory surgical center capacity, and payer scrutiny shapes purchasing and clinical adoption, prompting manufacturers to prioritize evidence demonstrating comparative effectiveness and procedural efficiency. Transitioning from hospital-centric care to decentralized settings has also spurred investment in training programs that help standardize ultrasound-guided techniques across diverse provider networks.

Across Europe, Middle East & Africa, regulatory harmonization and national reimbursement policies create a patchwork of access profiles that favor products with robust clinical data and clear cost-offset narratives. In many jurisdictions, clinicians emphasize long-term safety and quality-of-life metrics, and national procurement bodies often drive volume purchasing decisions that favor standardized, cost-effective options. Meanwhile, in the Asia-Pacific region, rapid adoption of innovative delivery techniques, a growing base of procedure-trained clinicians, and expanding domestic manufacturing capacity are reshaping competitive dynamics. Price sensitivity coexists with a strong interest in regenerative and minimally invasive approaches, encouraging hybrid strategies that combine localized production with targeted clinical evidence generation. Understanding these regional contours enables manufacturers and service providers to tailor regulatory strategies, distribution partnerships, and evidence programs to region-specific priorities and payer architectures.

Strategic company-level insights revealing how partnerships, portfolio integration, and evidence generation shape competitive advantages in joint pain injection offerings

Competitive dynamics among companies operating in the joint pain injection space reflect strategic moves to integrate product portfolios, expand service offerings, and secure distribution channels. Established pharmaceutical manufacturers continue to optimize corticosteroid and hyaluronic acid lines while selectively investing in specialty biologics and device-enabled delivery solutions. At the same time, device and diagnostic firms are partnering with biologic innovators to offer bundled solutions that combine injectables with guidance systems, procedural kits, and clinician training-strengthening the value proposition for providers and payers.

Newer entrants and mid-sized firms often differentiate through processing innovations for autologous therapies, streamlined disposables, or cost-effective kit designs that address site-of-care constraints. Across the competitive set, a consistent strategic theme is the pursuit of integrated evidence-generation programs that couple randomized clinical studies with real-world registries and patient-reported outcome capture. Additionally, companies are reallocating commercial investments toward outpatient channels, direct clinician education, and contracting models that align pricing with demonstrated outcomes. As a result, partnerships, licensing agreements, and selective vertical integration are emerging as preferred pathways to scale while managing regulatory complexity and capital intensity.

Actionable recommendations for manufacturers, clinicians, and payers to build supply resilience, validate clinical value, and accelerate adoption across care settings

Industry leaders should prioritize a set of pragmatic actions to translate insight into resilient growth and clinical impact. First, invest in supply chain resilience by diversifying suppliers, qualifying domestic manufacturing partners where feasible, and maintaining clear customs and classification strategies; doing so reduces exposure to tariff shocks and short-term disruptions. Second, commit to clinician training programs that emphasize ultrasound-guided delivery and standardized protocols, because procedural accuracy directly influences perceived effectiveness and payer acceptance.

Third, align product development with indication-specific evidence plans that address the clinical questions most relevant to payers and high-volume providers; this includes targeted outcomes for hip, knee, and shoulder interventions, and comparative analyses relative to systemic therapies in inflammatory conditions. Fourth, build modular commercial models that accommodate ambulatory surgical centers, hospitals, and specialty clinics, enabling flexible contracting and tiered pricing that reflect differing site-of-care economics. Fifth, pursue partnerships that integrate delivery devices, digital outcome capture, and post-market registries to substantiate value. Finally, adopt a patient-centric communications strategy that emphasizes safety, recovery timelines, and functional outcomes to improve uptake and reduce friction at the point of care. Collectively, these steps create an aligned playbook that balances short-term resilience with long-term clinical credibility.

Transparent description of the mixed-method research approach combining clinician interviews, supplier intelligence, regulatory review, and expert validation to produce robust insights

This analysis relied on a multi-method research approach that combined primary qualitative engagement with validated secondary intelligence to ensure balanced and auditable insights. The primary research included in-depth interviews with practicing orthopedic surgeons, rheumatologists, interventional radiologists, and procedure nurses, as well as structured discussions with procurement leads and regulatory experts across major regions. These interviews were supplemented by advisory-panel workshops that stress-tested hypotheses and prioritized evidence needs.

Secondary research incorporated review of peer-reviewed clinical literature, regulatory filings, product labels, and device guidance documents to map clinical indications, contraindications, and procedure protocols. The methodology also leveraged supplier and distributor interviews to assess supply chain pathways, lead times, and contractual norms. Data synthesis applied rigorous qualitative coding and triangulation to reconcile divergent viewpoints, and findings were validated through an expert review process to ensure credibility. Where appropriate, real-world practice patterns were inferred from clinical guidelines and procedural training curricula to contextualize adoption dynamics. Throughout, the research team adhered to transparent data provenance, strict conflict-of-interest checks, and iterative validation with clinical advisors to maintain robustness and relevance.

Concise conclusion drawing together clinical innovation, procedural trends, and commercial imperatives to define strategic priorities for stakeholders

The joint pain injection landscape is at an inflection point where clinical innovation, procedural precision, and commercial pragmatism intersect. Advances in biologic processing, more effective hyaluronic acid chemistries, and wider adoption of imaging-guided techniques are redefining expectations around safety and efficacy, while payer and procurement scrutiny drive the need for rigorous outcome evidence. At the same time, policy actions such as tariffs have emphasized the importance of supply chain strategy and local manufacturing decisions in preserving access and sustainable pricing.

For stakeholders across the value chain, the imperative is clear: align product development with indication- and route-specific evidence, invest in clinician training to secure consistent delivery quality, and adopt flexible commercial models that reflect diverse site-of-care economics. By doing so, manufacturers and providers can both improve patient outcomes and create defensible positions in a market characterized by rapid clinical evolution and intensified operational scrutiny. The next phase will reward organizations that marry clinical credibility with operational agility.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of biologic-based viscosupplementation formulas targeting advanced osteoarthritis pain
  • 5.2. Integration of platelet-rich plasma injections with personalized regenerative protocols for joint repair
  • 5.3. Expansion of long-acting corticosteroid formulations reducing injection frequency and improving compliance
  • 5.4. Growing investment in minimally invasive ultrasound-guided injection techniques for precise drug delivery
  • 5.5. Emergence of combination therapies blending hyaluronic acid with stem cell components for enhanced efficacy

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Joint Pain Injections Market, by Molecule Type

  • 8.1. Corticosteroids
    • 8.1.1. Betamethasone
    • 8.1.2. Methylprednisolone Acetate
    • 8.1.3. Triamcinolone Acetonide
  • 8.2. Hyaluronic Acid
    • 8.2.1. Cross-Linked
    • 8.2.2. Linear
  • 8.3. Platelet-Rich Plasma
    • 8.3.1. Leukocyte-Poor
    • 8.3.2. Leukocyte-Rich

9. Joint Pain Injections Market, by Indication

  • 9.1. Gout
    • 9.1.1. Acute Management
    • 9.1.2. Chronic Management
  • 9.2. Osteoarthritis
    • 9.2.1. Hip
    • 9.2.2. Knee
    • 9.2.3. Shoulder
  • 9.3. Rheumatoid Arthritis
    • 9.3.1. Large Joints
    • 9.3.2. Small Joints

10. Joint Pain Injections Market, by Route Of Administration

  • 10.1. Intra-Articular
    • 10.1.1. Landmark-Based
    • 10.1.2. Ultrasound-Guided
  • 10.2. Intramuscular
    • 10.2.1. Deep Tissue
    • 10.2.2. Superficial
  • 10.3. Peri-Articular
    • 10.3.1. Landmark-Based
    • 10.3.2. Ultrasound-Guided

11. Joint Pain Injections Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals
  • 11.3. Orthopedic Clinics
  • 11.4. Rheumatology Clinics

12. Joint Pain Injections Market, by Patient Age Group

  • 12.1. Adolescents
  • 12.2. Adults
  • 12.3. Elderly
  • 12.4. Pediatrics

13. Joint Pain Injections Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Joint Pain Injections Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Joint Pain Injections Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Sanofi S.A.
    • 16.3.2. Ferring Pharmaceuticals A/S
    • 16.3.3. Zimmer Biomet Holdings, Inc.
    • 16.3.4. Bioventus, Inc.
    • 16.3.5. Seikagaku Corporation
    • 16.3.6. Anika Therapeutics, Inc.
    • 16.3.7. Fidia Farmaceutici S.p.A.
    • 16.3.8. Merck & Co., Inc.
    • 16.3.9. Johnson & Johnson
    • 16.3.10. AbbVie Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. JOINT PAIN INJECTIONS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. JOINT PAIN INJECTIONS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. JOINT PAIN INJECTIONS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY BETAMETHASONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY BETAMETHASONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY BETAMETHASONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY BETAMETHASONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY BETAMETHASONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY BETAMETHASONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY METHYLPREDNISOLONE ACETATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY METHYLPREDNISOLONE ACETATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY METHYLPREDNISOLONE ACETATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY METHYLPREDNISOLONE ACETATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY METHYLPREDNISOLONE ACETATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY METHYLPREDNISOLONE ACETATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY TRIAMCINOLONE ACETONIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY TRIAMCINOLONE ACETONIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY TRIAMCINOLONE ACETONIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY TRIAMCINOLONE ACETONIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY TRIAMCINOLONE ACETONIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY TRIAMCINOLONE ACETONIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CROSS-LINKED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CROSS-LINKED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CROSS-LINKED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CROSS-LINKED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CROSS-LINKED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CROSS-LINKED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LINEAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LINEAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LINEAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LINEAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LINEAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LINEAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LEUKOCYTE-POOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LEUKOCYTE-POOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LEUKOCYTE-POOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LEUKOCYTE-POOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LEUKOCYTE-POOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LEUKOCYTE-POOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LEUKOCYTE-RICH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LEUKOCYTE-RICH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LEUKOCYTE-RICH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LEUKOCYTE-RICH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LEUKOCYTE-RICH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LEUKOCYTE-RICH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ACUTE MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ACUTE MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ACUTE MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ACUTE MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ACUTE MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ACUTE MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CHRONIC MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CHRONIC MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CHRONIC MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CHRONIC MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CHRONIC MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CHRONIC MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HIP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HIP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HIP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HIP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HIP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HIP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY KNEE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY KNEE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY KNEE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY KNEE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY KNEE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY KNEE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SHOULDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SHOULDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SHOULDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SHOULDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SHOULDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SHOULDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LARGE JOINTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LARGE JOINTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LARGE JOINTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LARGE JOINTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LARGE JOINTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LARGE JOINTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SMALL JOINTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SMALL JOINTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SMALL JOINTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SMALL JOINTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SMALL JOINTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SMALL JOINTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LANDMARK-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LANDMARK-BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LANDMARK-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LANDMARK-BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LANDMARK-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LANDMARK-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ULTRASOUND-GUIDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ULTRASOUND-GUIDED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ULTRASOUND-GUIDED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ULTRASOUND-GUIDED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ULTRASOUND-GUIDED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ULTRASOUND-GUIDED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY DEEP TISSUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY DEEP TISSUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY DEEP TISSUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY DEEP TISSUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY DEEP TISSUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY DEEP TISSUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SUPERFICIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SUPERFICIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SUPERFICIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SUPERFICIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SUPERFICIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SUPERFICIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LANDMARK-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LANDMARK-BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LANDMARK-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LANDMARK-BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LANDMARK-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LANDMARK-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ULTRASOUND-GUIDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ULTRASOUND-GUIDED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ULTRASOUND-GUIDED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ULTRASOUND-GUIDED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ULTRASOUND-GUIDED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ULTRASOUND-GUIDED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ORTHOPEDIC CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ORTHOPEDIC CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ORTHOPEDIC CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ORTHOPEDIC CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ORTHOPEDIC CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ORTHOPEDIC CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOLOGY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOLOGY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOLOGY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOLOGY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOLOGY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ADOLESCENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ELDERLY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ELDERLY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ELDERLY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ELDERLY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ELDERLY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ELDERLY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PEDIATRICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PEDIATRICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2025-2032 (USD MILLION)
  • TABLE 311. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2024 (USD MILLION)
  • TABLE 312. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2025-2032 (USD MILLION)
  • TABLE 313. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 314. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 315. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 316. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 317. LATIN AMERICA JOINT PAI